Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recommended by NICE, for adult patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC).

Authors' conclusions
The results of this comprehensive review are unique to NSCLC and will assist clinicians to make decisions regarding the treatment of patients with advanced NSCLC. The design of future lung cancer trials needs to reflect the influence of factors such as histology, genetics and the new prognostic biomarkers that are currently being identified. In addition, trials will need to be adequately powered so as to be able to test for statistically significant clinical effectiveness differences within patient populations. New initiatives are in place to record detailed information on the precise chemotherapy (and targeted chemotherapy) regimens being used, together with data on age, cell type, stage of disease and performance status, allowing for very detailed observational audits of management and outcomes at a population level. It would be useful if these initiatives could be expanded to include the collection of health economics data.

Final publication URL
http://www.hta.ac.uk/2238

URL for DARE abstract
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=12013041658& UserID=0

Link to NHS EED abstract
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=22013052625& UserID=0

Indexing Status
Subject indexing assigned by CRD

MeSH
Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Lung Neoplasms

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

**Address for correspondence**
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

**AccessionNumber**
32011001130

**Date abstract record published**
28/09/2011